Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to $5000.0.

  • Fate Therapeutics' Current Deferred Revenue fell 9916.67% to $5000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5000.0, marking a year-over-year decrease of 9916.67%. This contributed to the annual value of $393000.0 for FY2024, which is 4262.77% down from last year.
  • Latest data reveals that Fate Therapeutics reported Current Deferred Revenue of $5000.0 as of Q3 2025, which was down 9916.67% from $212000.0 recorded in Q1 2025.
  • In the past 5 years, Fate Therapeutics' Current Deferred Revenue ranged from a high of $42.2 million in Q4 2022 and a low of $5000.0 during Q3 2025
  • For the 5-year period, Fate Therapeutics' Current Deferred Revenue averaged around $13.5 million, with its median value being $1.9 million (2023).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 61956.89% in 2021, then crashed by 9916.67% in 2025.
  • Over the past 5 years, Fate Therapeutics' Current Deferred Revenue (Quarter) stood at $21.5 million in 2021, then surged by 96.56% to $42.2 million in 2022, then plummeted by 98.38% to $685000.0 in 2023, then tumbled by 42.63% to $393000.0 in 2024, then crashed by 98.73% to $5000.0 in 2025.
  • Its Current Deferred Revenue stands at $5000.0 for Q3 2025, versus $212000.0 for Q1 2025 and $393000.0 for Q4 2024.